Vanda Pharma Files 8-K on Officer/Director Changes & Compensation
Ticker: VNDA · Form: 8-K · Filed: Feb 21, 2024 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | Feb 21, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $983,112 K, $294,071, $320,580, $252,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Vanda Pharma just filed an 8-K about changes to its board or execs, and their pay, effective Feb 16!**
AI Summary
Vanda Pharmaceuticals Inc. filed an 8-K on February 21, 2024, reporting an event that occurred on February 16, 2024. The filing, under SEC File Number 001-34186, pertains to Item 5.02, which covers the departure or election of directors or officers and compensatory arrangements. The company, based in Washington, DC, with IRS Employer Identification No. 03-0491827, did not disclose specific names or dollar amounts in the provided excerpt.
Why It Matters
This filing signals potential shifts in Vanda Pharmaceuticals' leadership or executive compensation structure, which could influence future strategic decisions and financial performance.
Risk Assessment
Risk Level: medium — Changes in leadership or compensation can introduce uncertainty, but the specific details are not provided in this excerpt to assess the full impact.
Key Numbers
- 2024-02-16 — Earliest Event Date (Indicates when the reported event occurred.)
- 2024-02-21 — Filing Date (Date the 8-K was filed with the SEC.)
- 001-34186 — SEC File Number (Unique identifier for Vanda Pharmaceuticals Inc.'s SEC filings.)
- 202-734-3400 — Business Phone (Contact number for Vanda Pharmaceuticals Inc.)
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Registrant
- Delaware (company) — State of incorporation
- Washington, D.C. (company) — Principal executive offices city
- February 16, 2024 (date) — Date of earliest event reported
- February 21, 2024 (date) — Date of report filing
- 001-34186 (dollar_amount) — Commission File No.
- 03-0491827 (dollar_amount) — IRS Employer Identification No.
FAQ
What is the earliest event date reported in this 8-K filing?
The earliest event date reported in this 8-K filing is February 16, 2024.
When was this 8-K report filed with the SEC?
This 8-K report was filed with the SEC on February 21, 2024.
What is the primary item information covered by this 8-K filing?
The primary item information covered is "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers" (Item 5.02).
What is the Commission File Number for Vanda Pharmaceuticals Inc.?
The Commission File Number for Vanda Pharmaceuticals Inc. is 001-34186.
Where are Vanda Pharmaceuticals Inc.'s principal executive offices located?
Vanda Pharmaceuticals Inc.'s principal executive offices are located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037.
Filing Stats: 763 words · 3 min read · ~3 pages · Grade level 14.8 · Accepted 2024-02-21 16:32:11
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Ma
- $983,112 K — ive Officer and Chairman of the Board $983,112 Kevin Moran Senior Vice President, Chie
- $294,071 — Chief Financial Officer and Treasurer $294,071 Gunther Birznieks Senior Vice Presi
- $320,580 — Vice President, Business Development $320,580 Timothy Williams Senior Vice Presid
- $252,000 — ce President, Chief Marketing Officer $252,000 The Compensation Committee approved 2
- $933,000 — ive Officer and Chairman of the Board $933,000 80% Kevin Moran Senior Vice Presi
- $541,000 — Chief Financial Officer and Treasurer $541,000 45% Gunther Birznieks Senior Vice
- $560,000 — ce President, Chief Marketing Officer $560,000 45% In addition, the Compensation C
Filing Documents
- d796267d8k.htm (8-K) — 34KB
- 0001193125-24-041514.txt ( ) — 154KB
- vnda-20240216.xsd (EX-101.SCH) — 3KB
- vnda-20240216_lab.xml (EX-101.LAB) — 18KB
- vnda-20240216_pre.xml (EX-101.PRE) — 11KB
- d796267d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 21, 2024 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary